Search

Displaying results 1621 - 1630 of 10000 in total
  1. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. … , and improvements in CF symptoms.

  2. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    [L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998] … S1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes.

  3. Target

    Capsid protein

    go.drugbank.com/bio_entities/BE0010951
    TargetHepatitis B virus genotype A2 subtype adw2 (strain Rutter 1979)

    Phosphorylation of the capsid is thought to induce exposure of nuclear localization signal in the C-terminal portion of the capsid protein that allows binding to the nuclear pore complex via the importin

    Synonyms: Core antigen, Core protein
  4. Drug

    Debrisoquine

    go.drugbank.com/drugs/DB04840
    Approved

    An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.

  5. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … and a reduction in electrical nerve impulses.

  6. Drug

    Fluticasone furoate

    go.drugbank.com/drugs/DB08906
    ApprovedInvestigational

    Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].

  7. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Lomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]

    Synonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDE
  8. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion … Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.

  9. Drug

    Flotufolastat F-18

    go.drugbank.com/drugs/DB17851
    ApprovedInvestigational

    , and a high level of accumulation in tumors. … [A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive

  10. Drug

    Benzatropine

    go.drugbank.com/drugs/DB00245
    ApprovedInvestigational

    The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased … [A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500]